All News

Article

The Need for Comparative Treatment Trials in Psoriatic Arthritis

Richard Conway, MBBChBAO, PhD Nov 09, 2021

Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.

#Depression is associated with a 3x increased mortality risk in patients with incident #RA. 👉🏼Results from #DANBIO 👉🏼~11000 RA pts, ~1000 starting antidepressants Abs#1659 #ACR21 @RheumNow https://t.co/SsEjmLzacP https://t.co/1GiFE0KLjK

Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthrit…

Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6

#ACR21 L04 @rheumcat on #COVID19 in vaxed pts ▶️87 pts in @rheum_covid w/ ifn s/p full vax. 110 partial vax pts ⭐️25% (22/87) full vax pts hospitalized. 45% on BCDT. 8/22 hospitalized had lung disease, 5 no other co-morbidities. 5 deaths (23%). @RheumNow https://t.co/DB8C6jKvuU https://t.co/dxUwjTRxxb

https://bit.ly/306DwGa

You need to visit this nonprofit on the #ACR21 website and also their website https://t.co/8SrCHZUrk0 to help patients & doctors navigate getting the meds pts need. There are resources explaining step therapy and how to navigate access restrictions for patients. @rheumnow

https://letmydoctorsdecide.org/about

No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo

https://bit.ly/3D3tO6b

Dr Kwok on isolated axial disease in PsA. Seen in 2% of cohort. Significantly more likely to be HLA-B27 positive. Lower HAQ score. No obvious predictors of future development of peripheral disease. Abstr#1775 #ACR21 @RheumNow https://t.co/SqpaLjCrmm

#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout ⭐️Effectively brought down serum uric acid <5, dose-dependent ⭐️10% pts gout flare with urate lowering @Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ

https://bit.ly/2Yt45oD

Minority (African American and Hispanic) #SLE patients have worse #COVID19 outcomes – double whammy! Data from the @rheum_covid #ACR21 @rheumnow #abst1933

#ACR21 L07 - Rx for IBM?! ⭐️Depletion of KLRG1+ T cells - trial of ABC008 ⭐️Presented data from 3 patients in 1st human studies ▶️single SC 0.1 mg/kg dose depletes CD8+KLRG1+ cells wo safety concerns @Rheumnow https://t.co/1J8PrOqbWh

https://bit.ly/3mWUuzS

I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation Now there hope might be on the horizon Exciting to see the science & a feasible target #ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q

Phase 2 Placebo/Deucravacitinib 6mg/12mg od study ACR20 at 16 weeks of 31.8%/52.9%/62.7% respectively. Efficacy observed across TNFi and body weight subgroups. Safety profile similar to Phase 3 trials in patients with psoriasis @RheumNow #ACR21 Abst#1820 https://t.co/bOfEZdqN5Z https://t.co/EjMwWISM80

Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in…

#SLE patients with limited health literacy affects vulnerable black patients in multiple domains – worse disease activity/damage, physician/patient communication, worse patient centered care, and patient activation @mithurheum #ACR21 @rheumnow #ACRBest abst#L08

To be clear, for IBM: resignation 'not that long ago' = yesterday. Early days I know, but nothing like a plausible, feasible target to bring hope @UpToDate screenshot exciting times at #ACR21 @RheumNow https://t.co/WAEUtQagym

#ACR21 L10 TRAIL1: Pirfenidone for RA-ILD ⭐️Low pt enrollment due to pandemic, 1/2 of planned trial size ▶️ Unable to meet primary endpt (composite death+FVC) but met FVC markers. Most pronounced in UIP patterns on HRCT @Rheumnow https://t.co/HB7N9Wl9Dn https://t.co/muBEguAAja

https://bit.ly/3qkIsm1

#Sleep disturbance is common in #RA but does it correlate with disease activity? Results from >100 RA pts suggest yes. Many reported sleep disturbances, associated with both incr patient & physician-assessed disease activity. Abs#1666 #ACR21 @RheumNow https://t.co/ud2uMf25cI https://t.co/BE4UHPB0f1

Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthr…

RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Predicting RA, and Treatment of Subclinical Arthritis Dr. Meral K. El Ramahi ( @MeralElRamahiMD) shares the abstracts discussed at #ACR21 focusing on predicting RA and treating subclinical arthritis. https://t.co/DYgV43JpgT https://t.co/U2NfXrfYZU

https://bit.ly/3BVc9wa

My article on the potential use of BMI to guide biologic selection in RA. Discussing #ACR21 abstract 0588 by @MilenaGianfran @JYazdanyMD https://t.co/hxliSZ3IBS @RheumNow

The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis | …

Watch back our recap of the best from Day 2 of #ACR21 in the @RheumNow daily panel. With @AurelieRheumo @RheumNow @Yuz6Yusof @bella_mehta @_Castillo_Pedro https://t.co/ORTbV61c2C

Topics

All News

The Need for Comparative Treatment Trials in Psoriatic Arthritis

Do you get our email newsletter?